<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564107</url>
  </required_header>
  <id_info>
    <org_study_id>ML18044</org_study_id>
    <nct_id>NCT02564107</nct_id>
  </id_info>
  <brief_title>A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease</brief_title>
  <official_title>An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and effect on quality of life of oral
      ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease. The
      anticipated time on study treatment is 25 weeks, and the target sample size is 50
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of skeletal events according to Skeletal Morbidity Period Rate (SMPR)</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bone pain according to participant questionnaire</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption according to participant questionnaire</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum pyridinoline cross-linked carboxyterminal telopeptide of collagen type I (ICTP)</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 (SF-36) score</measure>
    <time_frame>Up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to approximately 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pain; Bone Neoplasms; Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Ibandronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.</description>
    <arm_group_label>Ibandronate</arm_group_label>
    <other_name>Bondronat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females at least 18 years of age

          -  Breast cancer

          -  Bone metastases

        Exclusion Criteria:

          -  Use of bisphosphonates within the last 3 months

          -  Prior use of gallium nitrate or metastron

          -  Severely impaired renal function

          -  Hypocalcemia or primary hyperparathyroidism

          -  Central nervous system (CNS) metastases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Chair</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shumen</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

